- CEO
- Yi DIng Chen
- Full Time Employees
- 926
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Beijing China
- IPO Date
- Oct 18, 2021
- Business
- Acrobiosystems Co., Ltd. (SZSE: 301080) is a global biotechnology enterprise specializing in the research, development, manufacture, and commercialization of critical biological reagents, assay kits, and analytical solutions for the biopharmaceutical, life science research, and in vitro diagnostics industries. Founded in 2010 and headquartered in Beijing, China, the company operates regional headquarters, research laboratories, and production facilities across China, the United States, Germany, Switzerland, the United Kingdom, and Japan. The company operates through several specialized subsidiaries and business divisions, including ACRODiagnostics, ACROBiosystems AG, ACROBiosystems GmbH, and the bioSeedin biopharmaceutical partnering platform.
The company offers an extensive portfolio of life science tools and customized solutions supporting the entire drug development pipeline from early target discovery and preclinical validation to clinical trials and commercial manufacturing. Its primary product and service lines include recombinant proteins, comprising immune checkpoint targets, cytokines, viral antigens, receptor enzymes, membrane proteins, biotinylated proteins, and fluorescent-labeled proteins; high-specificity research and diagnostic antibodies, including anti-idiotypic antibodies, pharmacokinetic assay antibodies, and biosimilar benchmark antibodies; immunoassay kits and detection reagents, including enzyme-linked immunosorbent assay (ELISA) kits, inhibitor screening assays, and immunogenicity test kits; cell engineering and culture reagents, including stable cell lines, reporter gene assays, organoid culture media, transfection reagents, and magnetic beads; specialized product lines and sub-brands, such as Aneuro for neurobiology and neurodegenerative disease research, ClinMax for clinical pathology and translational medicine, Resilient Supply for GMP-grade raw materials, CytoPak, SAFENSURE, ComboX, and GENPower; and comprehensive contract research services, including custom gene synthesis, protein expression and purification, antibody development, molecular interaction analytics via surface plasmon resonance (SPR) and bio-layer interferometry (BLI), and GMP-compliant bioprocess raw material manufacturing.
In recent operational and strategic developments, Acrobiosystems has expanded its advanced therapy raw material offerings and global regulatory accreditations. The company obtained Material Suitability Confirmation from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its GMP-grade Interleukin-15 (IL-15), accelerating regulatory clearance pathways for cell therapy developers. Under its Aneuro division, the company entered into a strategic collaboration with Diagnostic Biochips to co-develop and supply integrated in vivo electrophysiology probe systems, neural sensors, and specialized biochemical reagents for neurological drug discovery. Additionally, Acrobiosystems operationalized expanded GMP-grade manufacturing infrastructure and scaled its direct distribution and technical support networks across North America and Europe to support increasing global demand in cell and gene therapy (CGT), antibody-drug conjugate (ADC), and mRNA therapeutic pipelines.